Skip to main content

Peer Review reports

From: A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

Original Submission
24 Feb 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
14 Apr 2023 Reviewed Reviewer Report
22 Jun 2023 Reviewed Reviewer Report
4 Jul 2023 Author responded Author comments - Jean-David Fumet
Resubmission - Version 3
4 Jul 2023 Submitted Manuscript version 3
24 Jul 2023 Author responded Author comments - Jean-David Fumet
Resubmission - Version 4
24 Jul 2023 Submitted Manuscript version 4
27 Jul 2023 Author responded Author comments - Jean-David Fumet
Resubmission - Version 5
27 Jul 2023 Submitted Manuscript version 5
27 Aug 2023 Reviewed Reviewer Report
28 Sep 2023 Reviewed Reviewer Report
3 Oct 2023 Author responded Author comments - Jean-David Fumet
Resubmission - Version 6
3 Oct 2023 Submitted Manuscript version 6
5 Oct 2023 Reviewed Reviewer Report
9 Oct 2023 Author responded Author comments - Jean-David Fumet
Resubmission - Version 7
9 Oct 2023 Submitted Manuscript version 7
Publishing
16 Oct 2023 Editorially accepted
9 Nov 2023 Article published 10.1186/s12885-023-11534-6

You can find further information about peer review here.

Back to article page